Biodistribution and Transcript Quantification in Mouse Tissues Using ddPCR
The Executive Lens: Marie-Hélène Raigneau—From Serendipity to Leadership – Transforming Drug Development at Altasciences
Journal of Pharmacological and Toxicological Methods: Introducing the Sinclair Nanopig™ model—Preliminary genomic, proteomic, and hepatic CYP450 characterization for (bio)pharmaceutical safety assessment
ISSUE NO. 47 — Size Matters: The Sinclair Nanopig® as a Translational Non-Rodent Model in Preclinical Research
Drug developers and scientists are constantly looking for animal models that are cost effective, aligned with research goals, and allow for lower test article (TA) usage without sacrificing scientific integrity and regulatory approval.
In Issue 47 of The Altascientist, we take a closer look at what makes the Sinclair Nanopig® a scientifically appropriate and cost-effective non-rodent species for your preclinical programs, covering:
- the benefits and advantages of using minipig models
- test article usage comparison between Sinclair Nanopig® and canine models
- the history and regulatory acceptance of the Sinclair Nanopig®
- a case study on reduced emesis in the Sinclair Nanopig®
Minipigs in Preclinical Drug Development
In the continuum of preclinical drug development, the selection of appropriate animal models is crucial for providing the safety data that is required for a novel therapeutic to progress into clinical trials.
Volumetric Blood Microsampling and LC-MS/MS Quantitation: A Novel Approach for the Determination of an Anti-Tuberculosis Drug Panel
Lacrimal Gland Measurements in Most Common Preclinical Laboratory Animals
30 Years of Innovation in Drug Development: The Evolution of the Contract Research Organization
Over the past three decades, drug development has evolved rapidly—driven by new technologies, tighter timelines, and greater collaboration. CROs like Altasciences have transformed, shifting from service providers to strategic partners.